Cargando…

Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine

Introduction. Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists, frequently used in neurodegenerative conditions affecting the nigrostriatal pathway. Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) have dose-dependent differential affinity for...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Christopher W. T., Gallagher, Keith E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149619/
https://www.ncbi.nlm.nih.gov/pubmed/28018697
http://dx.doi.org/10.1155/2016/5472492
_version_ 1782474041349636096
author Miller, Christopher W. T.
Gallagher, Keith E.
author_facet Miller, Christopher W. T.
Gallagher, Keith E.
author_sort Miller, Christopher W. T.
collection PubMed
description Introduction. Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists, frequently used in neurodegenerative conditions affecting the nigrostriatal pathway. Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) have dose-dependent differential affinity for monoaminergic transporters, inhibiting the dopamine transporter at higher doses, thus increasing availability of synaptic dopamine, with the potential for similar impulse control side effects. Case Presentation. A 19-year-old Asian-American female with a history of depression developed new-onset stealing behaviors after an increase in her dose of duloxetine from 60 mg to 90 mg; she described these actions as “compulsive” and irresistible, later experiencing either relief or guilt, features compatible with an ICD. Her symptoms eventually subsided with continued use of 90 mg of duloxetine. Discussion. To the knowledge of the authors, this is the first report of a patient developing new-onset ICD behaviors after being placed on a higher dose of duloxetine, which can inhibit the dopamine transporter and cause difficulty with impulse control. The self-resolving nature of the symptoms may result from compensatory upregulation of dopamine transporters, increasing reuptake of dopamine. Asian populations may be at a higher risk due to the frequent occurrence of CYP2D6 polymorphisms, which decrease the conversion of duloxetine to its inactive metabolites.
format Online
Article
Text
id pubmed-5149619
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-51496192016-12-25 Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine Miller, Christopher W. T. Gallagher, Keith E. Case Rep Psychiatry Case Report Introduction. Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists, frequently used in neurodegenerative conditions affecting the nigrostriatal pathway. Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) have dose-dependent differential affinity for monoaminergic transporters, inhibiting the dopamine transporter at higher doses, thus increasing availability of synaptic dopamine, with the potential for similar impulse control side effects. Case Presentation. A 19-year-old Asian-American female with a history of depression developed new-onset stealing behaviors after an increase in her dose of duloxetine from 60 mg to 90 mg; she described these actions as “compulsive” and irresistible, later experiencing either relief or guilt, features compatible with an ICD. Her symptoms eventually subsided with continued use of 90 mg of duloxetine. Discussion. To the knowledge of the authors, this is the first report of a patient developing new-onset ICD behaviors after being placed on a higher dose of duloxetine, which can inhibit the dopamine transporter and cause difficulty with impulse control. The self-resolving nature of the symptoms may result from compensatory upregulation of dopamine transporters, increasing reuptake of dopamine. Asian populations may be at a higher risk due to the frequent occurrence of CYP2D6 polymorphisms, which decrease the conversion of duloxetine to its inactive metabolites. Hindawi Publishing Corporation 2016 2016-11-27 /pmc/articles/PMC5149619/ /pubmed/28018697 http://dx.doi.org/10.1155/2016/5472492 Text en Copyright © 2016 C. W. T. Miller and K. E. Gallagher. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Miller, Christopher W. T.
Gallagher, Keith E.
Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
title Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
title_full Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
title_fullStr Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
title_full_unstemmed Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
title_short Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
title_sort self-limited kleptomania symptoms as a side effect of duloxetine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149619/
https://www.ncbi.nlm.nih.gov/pubmed/28018697
http://dx.doi.org/10.1155/2016/5472492
work_keys_str_mv AT millerchristopherwt selflimitedkleptomaniasymptomsasasideeffectofduloxetine
AT gallagherkeithe selflimitedkleptomaniasymptomsasasideeffectofduloxetine